The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Share News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Kingswood buys wealth manager; Helios capacity grows

Mon, 15th Nov 2021 19:13

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Kingswood Holdings Ltd - London-based wealth manager - Agrees to acquire Money Matters Ltd, a privately owned wealth management business, primarily offering its services in the North East of England, for total cash consideration of GBP3.4 million, paid over 2 years. Notes GBP1.7 million will be paid immediately, with further GBP1.7 million paid on achievement of performance targets. Money Maters North East business holds about GBP115 million assets under administration from about 600 clients. Kingswood's UK CEO David Lawrence says: "We remain committed to perpetuating our stated growth strategy within the UK and internationally. This is our second acquisition of 2021 and we continue to have a strong pipeline of high-quality UK opportunities under negotiation, six of which are in exclusive due diligence as we continue to grow our financial planning and investment management reach across the UK. We expect to be making more announcements over the coming weeks.''

----------

Schroder Real Estate Investment Trust Ltd - invests in UK commercial real estate, seeking income and capital growth from active management - Exchanges or completes 13 new lettings, renewals and reviews which will generate GBP300,000 per annum of rental income and increase contracted rental income by GBP185,000 per annum since September 20. Notes set to deliver 80,000 square foot of operationally net zero carbon industrial, storage and distribution space at Stanley Green Trading Estate after receipt of a resolution to grant planning permission.

----------

Helios Underwriting PLC - London-based investment vehicle, which acquires and consolidates underwriting capacity at Lloyd's - Notes December 31 expected capacity value to rise to GBP60.2 million from GBP30.8 million a year earlier. Expecting to acquire 29 LLVs during 2021 with capacity of GBP35.4 million, which was valued at 2021 capacity prices at GBP18.0 million. Chief Executive Nigel Hanbury says: "I am delighted that the value of the capacity portfolio will increase to GBP60 million with the revaluation of the existing portfolio adding 9.6p to the tangible net asset value per share - a 6.6% increase." Company adds: "Helios continued to manage the capacity portfolio discarding unwanted syndicates and taking positions on syndicates, in particular syndicate 510 and syndicate 2689, taking the total additional capacity acquired at auction to GBP23.8 million for consideration of GBP2.6 million."

----------

Thalassa Holdings Ltd - British Virgin Islands-based investment company in real estate, fintech and robotics - Subsidiary id4 delivers "client space solution" to Swiss-based asset manager Geneva Management Group. "The id4 client space solution, delivered using cloud-based technology, will enable GMG to onboard clients remotely and to review KYC profiles periodically," company says.

----------

Insig AI PLC - London-based machine learning and data science firm serving asset management industry, formerly known as Catena - Signs proof of concept exercise with unnamed European asset manager with assets under management of several billion euros. "In this initial proof-of-concept exercise on one of the client's larger funds, valued in excess of EUR1 billion, Insig AI has been tasked to use its machine learning data and expertise to analyse and categorise the client's portfolio," company says.

----------

Diurnal Group PLC - Cardiff, Wales-based pharmaceutical company focused on hormonal diseases - US partner Eton Pharmaceuticals signs co-promotion deal for Alkindi Sprinkle with Tolmar Pharmaceuticals. As part of deal, Tolmar's 62-person sales force will promote Alkindi Sprinkle to their paediatric endocrinology targets alongside its own existing product. "Eton has indicated that it expects the co-promotion agreement to translate to significantly faster adoption of Alkindi Sprinkle and to accelerate the time to reach peak conversion of patients from existing therapy. The terms of Diurnal's licensing agreement with Eton are unaffected by Eton's agreement with Tolmar," Diurnal says.

----------

Panthera Resources PLC - gold exploration and development company with assets in West Africa and India - Settles agreements with Metal Mining India Private Ltd to buy its Indian joint venture partner for AUD1.8 million, just under GBP1 million. Issues 3.0 million shares and pays GBP500,000 to close deal. Notes ownership interest in the Bhukia and Taregaon projects in India via IGL has increased to 100%, giving Panthera a 95% interest, if prospecting licences are granted in the future.

----------

Mkango Resources Ltd - Vancouver-based explorer for rare earth elements - German subsidiary HyProMag Ltd creates new business HyProMag GmbH alongside Pforzheim University professor Carlo Burkhardt. HyProMag will own 80% of new business, while Burkhardt will take own remaining 20%. "Germany is a major producer and market for rare earth magnets in Europe, and the establishment of HyProMag GmbH provides a strong platform to grow the business in the region. Germany has no domestic sources of primary rare earths. Development of domestic sources of recycled rare earths via the patented HPMS is a significant opportunity to diversify and strengthen development of a more resilient rare earths supply chain in Europe," company explains.

----------

W Resources PLC- tungsten, tin and gold mining and exploring in Spain and Portugal - Raises GBP750,000 from placing 12.5 million shares at 6 pence each. "Following the award of the mining licence at the Régua tungsten mine in Portugal, the majority of the funds raised from the placing will be used to progress the mine development and to accelerate the environmental impact study report this quarter, as the team works towards first production in the second half of 2022," company says. Notes it will also use part of the funds at the La Parrilla mine in Spain to improve the laboratories, finished goods warehouse and spare parts warehouse. Enlarged share capital now 133.1 million.

----------

Bradda Head Lithium Ltd - Isle of Man-based exploration and mining services provider - Signs binding letter of intent for royalty agreement with Lithium Royalty Corp for 2% gross overriding royalty for sedimentary lithium claims in central Arizona. Value of agreement worth USD8 million. Notes USD2.5 million will be paid on closing of deal, USD2.5 million will be paid after Bradda obtains 1 million tonnes lithium carbonate equivalent; and finally, USD3 million to be paid after Bradda obtains 2.5 million tonnes lithium. Chief Executive Charles FitzRoy says: "We are delighted that Lithium Royalty Corporation has chosen to partner with us. This agreement further endorses the confidence in and inherent value that we believe our assets have; as well as in the future potential of the Company and our strategy given LRC's investment in Bradda."

----------

Chaarat Gold Holdings Ltd - gold miner in Armenia and mine developer in Kyrgyz Republic - Chief Financial Office Chris Eger to leave firm on November 30. Company says CFO will "pursue other opportunities". "Chris leaves with the board's appreciation and thanks for the role he has played in the development of Chaarat over the last three years," company adds. Starts search for replacement, and says current management team will assume Eger's responsibilities.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
2 Dec 2019 13:19

Diurnal submits application for 'Alkindi Sprinkle' to US FDA

(Sharecast News) - Specialty pharmaceutical company Diurnal Group has submitted a 'New Drug Application' (NDA) to the US Food and Drug Administration (FDA), for the regulatory approval of 'Alkindi Sprinkle', or hydrocortisone granules in capsules for opening, as a replacement therapy of adrenal insufficiency in infants, children and adolescents in the US, it announced on Monday.

Read more
21 Nov 2019 11:36

Diurnal Primary Focus Remains On Progressing Flagship Products

Diurnal Primary Focus Remains On Progressing Flagship Products

Read more
20 Nov 2019 11:36

Diurnal To Explore Further Tests As Testosterone Treatment Does Well

Diurnal To Explore Further Tests As Testosterone Treatment Does Well

Read more
24 Sep 2019 11:21

Diurnal Loss Narrows On Research Expenses And Alkindi Launch

Diurnal Loss Narrows On Research Expenses And Alkindi Launch

Read more
14 Jun 2019 14:26

Diurnal Shareholders Approve Placing, Open Offer Worth GBP6 Million (ALLISS)

(Alliance News) - Pharmaceutical firm Diurnal Group PLC's shareholders on Friday approved its GBP5.9 million fundraise completed earlier in the day.Diurnal, which focuses on patients or

Read more
28 May 2019 13:32

Diurnal Group launches placing and open offer to fund drug development

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced a conditional placing of new ordinary shares in the company and the launch of an open offer on Tuesday, in order to raise funds to progress the development and commercialisation of its products.

Read more
28 May 2019 10:49

Diurnal Raises GBP5 Million Via Placing; Plans GBP1 Million Open Offer (ALLISS)

LONDON (Alliance News) - Diurnal Group PLC said Tuesday it has raised around GBP5.4 million via a 20.6 million share placing priced at 26 pence per share and announced an open offer to raise up to

Read more
10 May 2019 09:36

Polar Capital Global Healthcare Lags Behind Benchmark In First Half

LONDON (Alliance News) - Polar Capital Global Healthcare Trust PLC said on Friday it lagged against its benchmark for the first half of its financial year, as the healthcare trust underperformed a

Read more
24 Apr 2019 15:50

Diurnal gets orphan drug designation for Alkindi in Australia

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Wednesday that its 'Alkindi' product - hydrocortisone granules in capsules for opening - had been granted orphan drug designation in Australia by the Therapeutic Goods Administration, for the indication 'replacement therapy of adrenal insufficiency (AI) in infants, children and adolescents from birth to 18 years old'.

Read more
24 Apr 2019 10:44

Diurnal Gets Orphan Drug Designation For Alkindi In Australia

LONDON (Alliance News) - Diurnal Group PLC on Wednesday said its adrenal insufficiency drug Alkindi has been granted a second patent and orphan drug designation in Australia.Shares in were

Read more
28 Mar 2019 08:35

Diurnal soars after securing Nordic distribution deal

(Sharecast News) - Diurnal's shares leapt on Thursday despite a widened interim loss as the company landed a marketing and distribution deal for its Alkindi treatment in Scandinavia.

Read more
21 Mar 2019 16:11

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 22 March Sanne GroupFull Year ResultsSmiths GroupHalf Year BootFull Year

Read more
20 Mar 2019 10:33

Diurnal Group upbeat following FDA meeting over 'Alkindi'

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Wednesday that, following a "positive" meeting with the US Food and Drug Administration (FDA), it intended to submit a new drug application (NDA) for 'Alkindi' (hydrocortisone granules in capsules for opening) in the fourth quarter of 2019 as previously planned, with final acceptance of the filing by the FDA expected in 2020.

Read more
25 Feb 2019 10:39

Diurnal expecting Israel launch of 'Alkindi' next year

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Monday that its marketing and distribution partner, Medison Pharma has successfully submitted a market authorisation application (MAA) for its 'Alkindi' (hydrocortisone granules in capsules for opening) product to the Ministry of Health in Israel.

Read more
10 Jan 2019 12:35

Diurnal Granted US Patent But Unsure Why Share Price Has Tripled

LONDON (Alliance News) - Diurnal Group PLC said on Thursday that, aside from the granting of a patent, it is unsure as to why its share price has tripled.Shares were 188% higher on Thursday

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.